Linked Life Data

20862750

Source:http://linkedlifedata.com/resource/pubmed/id/20862750

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
3
pubmed:dateCreated
2011-1-21
pubmed:abstractText
The use of docetaxel prolongs survival for patients with castrate-resistant prostate cancer (CRPC). Inhibition of vascular endothelial growth factor (VEGF) with bevacizumab may further enhance the antitumor effect of docetaxel and estramustine in patients with CRPC.
pubmed:grant
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
AIM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Feb
pubmed:issn
0008-543X
pubmed:author
pubmed:copyrightInfo
Copyright © 2010 American Cancer Society.
pubmed:issnType
Print
pubmed:day
1
pubmed:volume
117
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
526-33
pubmed:dateRevised
2011-11-17
pubmed:meshHeading
pubmed:year
2011
pubmed:articleTitle
A phase 2 study of estramustine, docetaxel, and bevacizumab in men with castrate-resistant prostate cancer: results from Cancer and Leukemia Group B Study 90006.
pubmed:affiliation
Department of Medicine, Washington University School of Medicine, St. Louis, Missouri, USA. picus@im.wustl.edu
pubmed:publicationType
Journal Article, Multicenter Study, Clinical Trial, Phase II, Research Support, N.I.H., Extramural